Paul Roepman
Overview
Explore the profile of Paul Roepman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
4814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Geurts B, Battaglia T, van Berge Henegouwen J, Zeverijn L, de Wit G, Hoes L, et al.
BMC Cancer
. 2023 Mar;
23(1):205.
PMID: 36870947
Background: In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the...
12.
Samsom K, Schipper L, Roepman P, Bosch L, Lalezari F, Klompenhouwer E, et al.
J Pathol
. 2022 Jul;
258(2):179-188.
PMID: 35792649
The current increase in number and diversity of targeted anticancer agents poses challenges to the logistics and timeliness of molecular diagnostics (MolDx), resulting in underdiagnosis and treatment. Whole-genome sequencing (WGS)...
13.
Pruis M, Groenendijk F, Badloe K, van Puffelen A, Robbrecht D, Dinjens W, et al.
Br J Cancer
. 2022 May;
127(4):776-783.
PMID: 35606463
Background: Biomarker-guided therapy in an experimental setting has been suggested to improve patient outcomes. However, trial-specific pre-screening tests are time and tissue consuming and complicate the personalised treatment of patients...
14.
Schipper L, Monkhorst K, Samsom K, Bosch L, Snaebjornsson P, van Boven H, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053600
With more than 70 different histological sarcoma subtypes, accurate classification can be challenging. Although characteristic genetic events can largely facilitate pathological assessment, large-scale molecular profiling generally is not part of...
15.
Hoes L, van Berge Henegouwen J, van der Wijngaart H, Zeverijn L, van der Velden D, van de Haar J, et al.
Clin Cancer Res
. 2022 Jan;
28(7):1402-1411.
PMID: 35046062
Purpose: Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We...
16.
Palassin P, Lapierre M, Pyrdziak S, Wagner A, Stehle R, Corsini C, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503257
Microsatellite instability (MSI) is related to the alteration of mismatch repair (MMR) genes and plays a key role in colorectal cancer (CRC) pathogenesis. We previously reported that the transcription factor...
17.
van der Wijngaart H, Hoes L, van Berge Henegouwen J, van der Velden D, Zeverijn L, Roepman P, et al.
Clin Cancer Res
. 2021 Sep;
27(22):6106-6114.
PMID: 34475104
Purpose: To assess the efficacy of olaparib, a PARP inhibitor (PARPi) in patients with tumors with mutations, regardless of histologic tumor type. Patients And Methods: Patients with treatment-refractory mutated cancer...
18.
Simons M, Retel V, Ramaekers B, Butter R, Mankor J, Paats M, et al.
Pharmacoeconomics
. 2021 Aug;
39(12):1429-1442.
PMID: 34405371
Background: Advanced non-small-cell lung cancer (NSCLC) harbours many genetic aberrations that can be targeted with systemic treatments. Whole-genome sequencing (WGS) can simultaneously detect these (and possibly new) molecular targets. However,...
19.
van de Haar J, Hoes L, Roepman P, Lolkema M, Verheul H, Gelderblom H, et al.
Nat Med
. 2021 Aug;
27(9):1553-1563.
PMID: 34373653
Genomic profiling is critical for the identification of treatment options for patients with metastatic cancer, but it remains unclear how frequently this procedure should be repeated during the course of...
20.
Meggendorfer M, Jobanputra V, Wrzeszczynski K, Roepman P, de Bruijn E, Cuppen E, et al.
Semin Cancer Biol
. 2021 Jun;
84:16-22.
PMID: 34119643
Interrogating the tumor genome in its entirety by whole-genome sequencing (WGS) offers an unprecedented insight into the biology and pathogenesis of cancer, with potential impact on diagnostics, prognostication and therapy...